cAMP is an essential signalling molecule whose concentration in cells is regulated by a wide range of hormones. A large number of diseases, including cancer and asthma, are linked to improper regulation of the cAMP signalling system, and manipulation of cAMP levels by pharmaceutical agents has proven therapeutic benefit. The action of cAMP in cells is mediated through the signalling enzymes PKA (protein kinase A) and EPAC (exchange protein directly activated by cAMP). The study of the function of these proteins is essential to understand the role of cAMP in controlling disease. We have found that EPAC interacts with an ancillary protein, called LC2 (light chain 2), and this interaction enhances EPAC's ability to activate its substrate protein, Rap1 GTPase. This is an important finding because Rap1 is involved in the control of cell migration and cell shape, functions that are disrupted in diseases like cancer. LC2 appears to enhance EPAC activity towards Rap1 by increasing the ability of EPAC to interact with cAMP, so that EPAC activation occurs at lower concentrations of cAMP. The design of inhibitors that disrupt or enhance EPAC1-LC2 interaction may therefore form the basis of future therapeutics for diseases where cAMP signalling through Rap1 is improperly regulated.
Introduction
Many extracellular physiological signalling agents increase the intracellular levels of the ubiquitous second messenger cAMP [1] . These include immunomodulators, neurotransmitters and hormones, which typically activate the seventransmembrane domain class of G-protein-coupled receptors [1] . Ligand binding causes activation of heterotrimeric G-protein, G s α, which stimulates one or more isoforms of adenylate cyclase, to catalyse production of cAMP. Intracellular levels of cAMP are then regulated through the action of cAMP PDEs (phosphodiesterases), which degrade cAMP to 5 -AMP [2] . cAMP serves as a pivotal second messenger that regulates a diverse range of key cellular processes. These include central metabolic events, including gluconeogenesis, glycogenolysis and lipogenesis, cardiac and smooth muscle contraction, secretory processes, ion channel conductance, learning and memory, cell growth and differentiation, apoptosis and inflammatory responses.
Given the importance of cAMP in regulating physiological processes, it is perhaps not surprising that a wide range of disease states are linked to improper regulation of the cAMP signalling system [3] . For example, a constitutively activated G s α mutant leads to McCune-Albright syndrome and benign neoplasia in cells for which increased cAMP is mitogenic [3] . This causes autonomous, elevated cAMP production leading to endocrine hyperplasia and hyperfunction [3] . cAMP is known to stimulate both of these responses in many endocrine glands, including gonads, adrenal cortex, thyroid, and pituitary somatotrophs [3] . Manipulation of cAMP levels by pharmaceutical agents also has proven therapeutic benefit. For example, selective inhibitors of cAMP-specific PDEs have anti-inflammatory and anti-depressant properties [4, 5] .
Until very recently the intracellular effects of cAMP were thought to be transduced solely by PKA (cAMP-dependent protein kinase; protein kinase A) in most cell types [6] . More recently, however, there have been consistent reports that certain signalling actions of cAMP are not mediated by PKA [7, 8] . Insight into this very important, new PKAindependent signalling system has arisen from attempts to delineate the pathway by which cAMP activates the small GTPase, Rap1 [7, 8] . These studies implicate direct activation of Rap1 by a family of GEFs (guanine nucleotide-exchange factors) called cAMP-GEFs or EPACs (exchange proteins directly activated by cAMP), with no involvement of PKA [7, 8] . EPACs represent a novel mechanism for governing signalling specificity within the cAMP cascade.
EPAC1 and EPAC2 are multidomain proteins (Figure 1 ) containing an autoinhibitory cAMP-binding domain ( Figure 1 ; CAMP) that inhibits the catalytic region and a DEP (dishevelled, Egl-10 and pleckstrin homology) domain, which Left panel: AH109 yeast cells were co-transformed with the empty bait vector, pGBKT7, or pGBKT7 containing EPAC1, EPAC1-DEP or EPAC1-cAMP and the empty 'library vector', pACT2 or pACT2-LC2. After 2 or 3 days, cells were spotted on to -Ade/ -His/-Leu/-Trp agar plates containing X-Gal to check for activation of β-galactosidase expression. To check that the ratio of expression levels of constructs was equal, protein extracts were separated by SDS/PAGE and immunoblotted with an anti-HA-epitope (where HA stands for haemagglutinin) monoclonal antibody (to detect LC2) and an anti-Myc-epitope monoclonal antibody (to detect EPAC1, EPAC1-DEP and EPAC1-cAMP). In all experiments, EPAC1-cAMP showed reduced interaction with LC2. Right panel: to check for the ability of GST-fusion proteins to interact with LC2, PC12 cell lysates were precipitated with GST-DEP, GST-REM (Ras exchange motif), GST-cAMP or GST-CAT (catalytic domain). Cell lysates and precipitates were then separated by SDS/PAGE, followed by immunoblotting with the LC2 polyclonal antibody.
In all experiments, LC2 was found to interact with GST-cAMP but not with GST-DEP, GST-REM or GST-CAT.
is thought to be involved in membrane localization [9] . The presence of cAMP-binding sites in EPAC proteins facilitates their direct activation by cAMP, independent of the activation of PKA [7, 8] . EPAC2 has an additional cAMP-binding site in its N-terminus that binds cAMP with low affinity [9] . EPAC1 mRNA is broadly expressed, with particularly high levels occurring in the thyroid, ovary, kidney and certain brain regions, whereas expression of EPAC2 mRNA appears to be restricted to the brain and adrenal glands [7, 8] .
EPAC forms a multiprotein complex with MAP (microtubule-associated protein) LCs (light chains)
The recruitment of signalling proteins to specific complexes within cells underpins the functioning of most, if not all, signalling pathways. The machinery that underpins this for cAMP is now becoming apparent [10] [11] [12] . Thus adenylate cyclase and G s α can be localized to discrete plasma-membrane regions. Gradients of cAMP are then established through PDE action, with anchored species presumed to tailor localized cAMP gradients. PKA populations localized at specific intracellular sites, by binding to anchor proteins [AKAPs (A-kinase anchoring proteins)], sample these gradients to provide a compartmentalized response [11, 12] . From our investigations, we have identified EPAC as a cAMPactivated enzyme that is also regulated by protein complex formation.
Using a combination of yeast two-hybrid analysis and co-immunoprecipitation, we have identified the LC2 of MAP1A as a novel protein-binding partner for EPAC1 and EPAC2 [13] . The MAP1A/LC2 gene is organized to encode a precursor polypeptide that undergoes proteolytic processing to generate the final 2556-amino-acid MAP1A heavy chain and 249-amino-acid LC2 polypeptide [14] . LC2 belongs to a family of MAP LCs, including LC1 and LC3, which appear to serve as a 'scaffold' or 'adaptor' proteins, facilitating the stable interaction of MAPs with other signal-transduction components or structural proteins. Using deletion analysis and GST (glutathione S-transferase)-protein chimaeras of individual EPAC1 domains, we have identified the cAMPbinding domain of EPAC as being responsible for mediating interaction with LC2 [13] .
LC2 enhances EPAC activity towards Rap1
LC2 appears to have direct effects on the ability of EPAC1 to activate Rap1 by interacting with the EPAC1 cAMP-binding domain [15] . This appears to be through direct interaction with EPAC1 since competition with an antibody raised against the EPAC1 cAMP-binding domain prevents the binding of endogenous LC2 to the cAMP-binding domain of endogenous EPAC1 and completely ablates basal and stimulated Rap1 levels in PC12 cell lysates [15] . Furthermore, our results suggest that the amplification of stimulated Rap1 levels by LC2 may be through as yet undetermined conformational changes in the cAMP-binding domain of EPAC1 [15] . This is based on two lines of evidence. First, co-transfection of LC2 with EPAC1 lowers the minimal dose of EPAC-specific 8-(4-chlorophenylthio)-2 -O-methyladenosine-3 ,5 -cAMP required to activate Rap1 [15] . Secondly, LC2 appears to enhance the ability of the cAMP-binding domain of EPAC1 to interact directly with immobilized cAMP [15] . LC2 therefore appears to be an enhancer of EPAC1 function by increasing the sensitivity of EPAC1 to activation by cAMP (Figure 2 ). To our knowledge, this is the first example of protein interaction that can positively alter the affinity of a cAMP-binding subunit for cAMP.
In this respect, the cAMP-binding domain of EPAC1 is thought to have a lower sensitivity to cAMP than PKA in vivo [9] . Half-maximal activation of PKA occurs in vitro at approx. 1 µM cAMP, whereas half-maximal activation of EPAC1 occurs at 40 µM [9] . It could be envisaged that through direct protein interaction with suitable binding partners like LC2, the activation of EPAC1 by cAMP could be 'tuned' to sensitivities approaching those of PKA. This could occur in a tissue-specific manner, thereby adapting the cAMP/ EPAC1/Rap1 pathway to the requirements of particular cell types. Clearly, LC2 peptide mimetics, or inhibitors of LC2-EPAC interaction, may form the future basis for novel therapeutics, based on the ability to modulate the sensitivity of the cAMP/EPAC pathway to elevated or diminished cellular cAMP levels that occur in certain disease states.
